Objectives: To evaluate the feasibility of different methods for susceptibility testing of human Arcobacter isolates, to assess susceptibility to antibiotics commonly used to treat diarrhoeal illness and to obtain MIC distribution data.
Introduction
Campylobacteriosis is the most reported zoonotic disease in humans in industrialized countries with a continuous increase in cases over recent years. 1 With the exception of Campylobacter jejuni and Campylobacter coli, the clinical importance of Campylobacter species and related genera is much less investigated. 2 In 1991, a new genus, Arcobacter, was introduced within the family of Campylobacteraceae. Arcobacters are present in the digestive tract of healthy animals such as poultry, pigs, sheep and cattle, but can be associated with enteritis in animals and may play a pathogenic role in reproductive disorders in cattle, pigs and sheep. Arcobacter transmission to humans is mediated by contaminated foods and water, and poultry products act as an important reservoir. 3 Three species, Arcobacter butzleri, Arcobacter cryaerophilus and Arcobacter skirrowii, have been associated with enteritis, colitis and septicaemia. In two studies, Arcobacter was even ranked fourth as the bacterial pathogen causing diarrhoeal illness. 4, 5 Macrolides have become first-choice empirical therapy in gastrointestinal infections caused by Campylobacter spp. because of increasing resistance rates to fluoroquinolones, ampicillin and doxycycline. 6 Recently, azithromycin has been proposed as the primary choice to treat traveller's diarrhoea. 7 The aim of the study was to assess susceptibility of Arcobacter isolates from humans with gastrointestinal disease in a routine microbiology laboratory.
Methods
We examined 106 unique clinical strains of Arcobacter spp., 63 A. butzleri and 43 A. cryaerophilus, collected between 2008 and 2014 and originating from stool samples of patients with gastrointestinal illness. 5 Strains were identified by multiplex PCR and PCR -RFLP, and characterized by PFGE. T and Staphylococcus aureus ATCC 25923 (disc diffusion testing) were included with each separate run. EUCAST breakpoints for C. coli were used for erythromycin, ciprofloxacin, tetracycline and doxycycline. For ampicillin MIC, EUCAST non-species-related breakpoints were used, for ampicillin disc diffusion and for gentamicin MIC and disc diffusion, EUCAST Enterobacteriaceae breakpoints were applied. 9 A subset of 18 strains, 9 A. butzleri and 9 A. cryaerophilus, was analysed to determine the presence of mutations in the quinolone resistancedetermining region (QRDR) of the gyrA gene. Sequencing of the QRDR of the gyrA gene was performed. Conventional PCR using F-QRDR (5 ′ -TGG ATT AAA GCC AGT TCA TAG AAG-3 ′ ) and R2-QRDR (5 ′ -TCA TMG WAT CAT CAT AAT TTG GWA C-3 ′ ) primers generated a 344 bp PCR fragment of the gyrA gene.
10 PCR products were sequenced on both strands by BaseClear BV (the Netherlands). Multiple sequence alignment was carried out using CodonCode Aligner 1.5.1 and Clustal Omega 1.2.1. 11 The gyrA sequences of A. butzleri LMG 10828 T and A. cryaerophilus LMG 24291 T were used as references.
Results
The susceptibility results obtained by gradient strip diffusion for 106 Arcobacter spp. isolates are shown in Table 1 Azithromycin was tested on a subset of A. butzleri (n¼20) and A. cryaerophilus (n¼20).
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breakpoint was observed, whereas for gentamicin, a monomodal distribution below the breakpoint was noticed. The azithromycin test results of a pilot set of 40 strains resulted in categorical agreement with erythromycin for all strains. Combined resistance to erythromycin and ciprofloxacin was observed in 8% of the strains with a predominance for A. cryaerophilus (six of eight strains), while combined resistance to erythromycin and doxycycline (12%) was mainly observed in A. butzleri (10 of 13 strains). Multidrug resistance to erythromycin, ciprofloxacin and doxycycline was detected in only 2% (n¼ 2) of the strains. Susceptibility results with disc diffusion showed an overall 60% agreement with gradient strip diffusion ( Table 2) 
Discussion
Data on susceptibility of Arcobacter spp. are scarce despite the need for therapeutic guidance in selected patient groups. Comparing susceptibility results of Arcobacter isolates can be hazardous because of the use of divergent techniques and interpretation guidelines or when small datasets are reported. Comparison of the present study results with data from other studies in humans and animals shows similar MIC 50 values for all tested antibiotics. 12 -16 MIC 90 values also remain in the same range except for ciprofloxacin for which a pronounced increase from ,0.5 to .16 mg/L was observed over a 10 year time span, suggesting acquired resistance. A recent multicentre study in Belgium in 2013 on Campylobacter isolates from human stool revealed resistance of 49.5% to ciprofloxacin, 34.7% to tetracycline and 1% to erythromycin. 17 In the present study on Arcobacter, erythromycin resistance (19%) is much higher. Together with an overall resistance to ciprofloxacin of 28%, these results preclude the use of both antimicrobials in the treatment of Arcobacter colitis. The high level of resistance of A. cryaerophilus isolates to ciprofloxacin warranted a molecular investigation into the acquisition of point mutations in gyrA DNA. These alterations predominantly occur in gyrA and parC genes. The sample of 18 isolates showed clear discrimination between a group of high-level ciprofloxacinresistant isolates carrying a mutation at position 254 of the gyrA gene and a ciprofloxacin-susceptible group lacking this mutation. The manifest bimodal distribution of fluoroquinolone MIC distribution curve in A. cryaerophilus supports this mechanism of acquired resistance.
Categorical agreement between azithromycin and erythromycin results was as expected. For Campylobacter, the epidemiological cut-off values (ECOFF) of azithromycin are 4-fold lower than these of erythromycin. Based on this observation, the equal or even higher azithromycin MICs compared with those of erythromycin for the individual Arcobacter isolates are rather surprising. To justify the calculation of ECOFFs our actual dataset is too limited. At least 300 data points from three different test sites are required. 18 Yet, these ECOFFs could guide us to indicate the upper limits of the WT population.
An important factor in the development of resistance of Campylobacter and Campylobacter-like organisms is the uncontrolled use of antibiotics in animal husbandry. CDC has documented resistance to ciprofloxacin in almost 25% of human Campylobacter strains tested and resistance to azithromycin in about 2%. 19 Costs are expected to be higher for infections with resistant pathogens. The European Food Safety Agency advises to collect relevant and comparable data on zoonoses, zoonotic agents, antimicrobial resistance and foodborne outbreaks and states that monitoring and reporting of antimicrobial resistance data on Campylobacter is mandatory. 20 They included a chapter entitled 'Farm-to-fork analysis' on resistance along the food chain for C. jejuni and C. coli versus ciprofloxacin and erythromycin, aiming to highlight potential links between resistance occurring in Campylobacter and Campylobacter-like organisms in animals, foods derived from those animals and humans.
In conclusion, susceptibility testing on Arcobacter isolates is feasible in a routine microbiology laboratory, taking into account the proposed adaptations of testing conditions. Gradient strip methodology is preferred. Susceptibility testing in special patient populations with gastroenteritis caused by Arcobacter spp. may be necessary to guide patient-tailored therapy. Resistance to fluoroquinolones is manifestly present in A. cryaerophilus, while A. butzleri remain almost fully susceptible. Macrolides, preferred agents in Campylobacter infections, are not first-choice antibiotics with Arcobacter infections for which tetracycline can be proposed. Arcobacter susceptibility testing in Belgian patients
